

### PHILIPPINE HEART CENTER

**Office of Strategy Management** 

## BALANCED SCORECARD ACCOMPLISHMENT AND COMPARATIVE SUMMARY REPORT

January – December 2020



· Impact

Strategic Position

#### PHILIPPINE HEART CENTER

### **STRATEGY MAP 2019-2022**

VISION The Philippine Heart Center is the leader in upholding the highest standards of cardiovascular care, a self-reliant institution responsive to the health needs of the Filipino people by 2022

Better health outcomes in Cardiovascular diseases and Responsive Health System

**Healthier Filipino Hearts** 

Position Philippine Heart Center as the leader in cardiovascular care at par with global benchmarks

Position Philippine Heart Center as the country's lead advocate in the prevention of cardiovascular diseases

Provide comprehensive and responsible patient care using multi-disciplinary best practice standards

Expand local and international training for advanced cardiovascular procedures

Prioritize institutional research on advanced cardiovascular procedures to impact national health policies

Strengthen linkages with stakeholders for prevention and treatment of CV diseases nationwide

Provide comprehensive
Employee Career training and
progression pathway to
enhance employee
engagement

Promote heartfelt cardiovascular care through positive patient experience

Upgrade hospital facilities for positive practice environment and stakeholders' satisfaction

Provide technology solutions to improve operational efficiency

Ensure prudent and efficient asset management

**MISSION** We shall provide comprehensive cardiovascular care enhanced by education and research that is accessible to all

CORE VALUES Patient-Focused Care | Compassion Integrity | Respect | Excellence

Approved by:

JOEL M. ABANILLA, MD Executive Director, PHC

Core

Support Process

	Impact Indicator	#	Measure	BL	Target	Actual Q1	Actual Q2	Actual Q3	Actual Q4	% ACC
	Healthier	1	National Cardiac (Heart) Mortality Rate	<b>22.3</b> % (2013- DOH)	22.0%			5 <b>.7%</b> : 2019)		140.1%
A	Filipino Hearts	2	Health Outcomes RHCs  Mortality Z-Benefit  Cardiac Surgery	<b>3.2</b> % (4/124)	3.5%	<b>0</b> % (0/32)	<b>3.0</b> % (1/33)	<b>2.6</b> % (1/38)	<b>7.5%</b> (3/40)	46.7% (3.5/7.5)
		3	Health Outcomes of PHC Net Overall Mortality Rate	<b>4.6</b> % (712/ 15,537)	5.0%	<b>5.3</b> % (170/3,210)	<b>5.5</b> % (226/4,088)	<b>6.0</b> % (332/5,492)	<b>6.3</b> % (480/ 7,616)	79.4% (5/6.3)
В	Better Health Outcomes	4	Decrease mortality from Cardiovascular disease	<b>7.5</b> % (360/8,409)	<5%	<b>6.9</b> % (110/ 1,583)	<b>8.5</b> % (1 <i>55/</i> 1,821)	<b>9.1</b> % (226/2470)	<b>9.6%</b> (343/ 3581)	52.1% (5/9.6)
		5	Hospital Acquired Infection Rate	<b>0.63</b> % (100/ 1 <i>5,</i> 786)	1.10%	. <b>33</b> % (8/ 2,399)	. <b>36</b> % (10/ 2,814)	. <b>47</b> % (20/ 4,268)	.45% (29/ 6 <b>,</b> 446)	244.4% (1.1/.45)
O	Responsive Health Systems	6	% of Client with Very Satisfactory Rating	<b>57.9</b> % (4,278/7,390)	60.0%	60.8%	<b>58.4</b> % (793/ 1,357)	<b>58.5</b> % (1,004/1,719)	<b>66.0</b> % (1,873/ 2,838)	110.0% (66/60)
		7	% NBB-Eligible patients with zero Co payment	<b>92.2</b> % (1,893/,053)	93.0%	<b>94.0%</b> (466/ 496)	<b>96.6</b> % (854/ 884)	<b>97.2</b> % (1,276/ 1,313)	<b>97.8</b> % (1,703/ 1,741)	105.2% (97.8/ 93)

**IMPACT** 

#### STRATEGIC GOAL

	Goal	#	Measure	BL	Target	Actual Q1	Actual Q2	Actual Q3	Actual Q4	% ACC
D	Position Philippine Heart Center as the leader in cardiovascular care at par with global benchmarks	8	Number of cardiovascular procedures with health outcomes at par or better than global benchmarks	16	12	11	14	14	10	83.3% (10/12)
E	Position Philippine Heart Center as the country's lead advocate in the prevention of cardiovascular diseases	9	Number of PHC research/ programs on prevention adopted as national policy	6	7	6	6	6	6	85.7% (6/7)

#### **CORE PROCESSES**

	Objective	#	Measure	BL	Targ et	Actual (Q1)	Actual (Q2)	Actual (Q3)	Actual (Q4)	% ACC
	Provide comprehensive and responsible	10	No. of clinical pathways developed and implemented	22	18	22	22	22	22	122.2% (22/18)
F	patient care using multi- disciplinary best practice standards	11	Percentage compliance to approved clinical pathways	<b>57.3%</b> (775/1,352) CABG: 42.5% VSD: 88.4% TOF: 93.7%	70.0%	60.3% (140/232) CABG: 50.9% ( 84/165) VSD: 77.1% (27/35) TOF: 90.6% (29/32)	60.9% (143/235) CABG: 50.9% ( 86/167) VSD: 77.1% (27/35) TOF: 90.6% (30/33)	57.6% (181/314) CABG: 50.9% (105/224) VSD: 80.0% (40/50) TOF: 90.0% (36/40)	52.8% (216/409) CABG: 38.5% (110/286) VSD: 85.7% (54/63) TOF: 86.7% (52/60)	75.4% (52.8/70)
	Expand local and international	12	Number of new training programs developed	14	11	4 1. Pedia Cardio Clinical Research Fellowship 2. Fellowship in Advance Cardiac Imaging 3. CV Surgery Clinical Research Fellowship ( Advance Aortic Surgery) 4. RFRHD Module	4 1. Pedia Cardio Clinical Research Fellowship 2. Fellowship in Advance Cardiac Imaging 3. CV Surgery Clinical Research Fellowship ( Advance Aortic Surgery) 4. RFRHD Module	4 1. Pedia Cardio Clinical Research Fellowship 2. Fellowship in Advance Cardiac Imaging 3. CV Surgery Clinical Research Fellowship ( Advance Aortic Surgery) 4. RFRHD Module	12 5. Updates of ECC during Covid 6. Blended PALS 7. Blended ACLS 8. Blended BLS 9. Safety Webinar on Covid 10. Multidisciplinary Covid Series 11. PPE 12. ACI ROPs	109.1% (12/11)
G	training for advanced cardiovascular procedures	13	Number of graduates of new Fellowship training programs / Hospitals with completed module	1 Fellow/Program     39 hospitals-PGS Module 1     5 hospitals-PGS Module 2     5 hospitals-Clinical Pathway     PTP- 22	1/ program	1. Pedia Cardio Clinical Research Fellowship- 1 ongoing 2. CV Surgery Clinical Research Fellowship ( Advance Aortic Surgery)- 1 ongoing	1. Pedia Cardio Clinical Research Fellowship- 1 ongoing 2. CV Surgery Clinical Research Fellowship ( Advance Aortic Surgery)- 1 ongoing	1. Pedia Cardio Clinical Research Fellowship- 1 ongoing 2. CV Surgery Clinical Research Fellowship ( Advance Aortic Surgery)- 1 ongoing	1. Pedia Cardio Clinical Research Fellowship- 1 ongoing 2. CV Surgery Clinical Research Fellowship ( Advance Aortic Surgery)- 1 ongoing	100.0%

#### **CORE PROCESSES**

	Objective	#	Measure	BL	Target	Actual (Q1)	Actual (Q2)	Actual (Q3)	Actual (Q4)	% ACC
	Prioritize institutional research on advanced cardiovascul ar procedures to impact national health policies	14	Number of research outputs published & presented	<b>123.2%</b> (142/ 175)	90.0%	<b>93.3</b> % (14/15)	<b>116.0</b> % (161/139)	60.9% (42/69) ( corrected formula)	<b>72.9</b> % (62/85)	81.0% (72.9/ 90)
Н		15	Number of research outputs completed for policies on prevention and benchmark procedures	9	11	10	11	15	24	218.2% (24/11)
ı	Strengthen linkages with stakeholders for prevention	16	Number of independent regional heart centers	4 1.SPMC 2.VSMMC 3.NMMC 4.WVMC	5	4	4	4	4	80.0% (5/4)
	and treatment of CV diseases nationwide	17	Beneficiaries of barangay-based PhilPrevent program	2 1. Sitio Ruby 2 <sup>nd</sup> Phase Intervention 2. Taguig- RFRHD	3	2	2	2	2	66.7% (2/3)

#### SUPPORT PROCESSES

	Objective	#	Measure	BL	Target	Actual (Q1)	Actual (Q2)	Actual (Q3)	Actual (Q4)	% ACC
	Provide comprehensive	18	Percentage increase in employment satisfaction survey	<b>93.1</b> % (1,634/1,756)	93.0%	No Survey Conducted ( Jan-Mar)	No Survey Conducted ( Jan-Jun)	Online Survey by Oct. 2020	<b>92.8</b> % (805/867)	103.2% (92.8/93)
J	Employee Career training and progression pathway to	19	Percentage of filled additional plantilla positions	NA	50.0%	1 <b>00</b> % (32/32)	<b>100.0</b> % (32/32)	<b>78.1</b> % (25/32)	<b>78.1</b> % (25/32)	156.2% (78.1/50)
	enhance employee engagement	20	PRIME-HRM Level	100.0% (submitted 4/4)	100.0%	<b>18.0%</b> (390/2171)	<b>44.7</b> % (971/2171)	<b>50.0</b> % (2/4)	<b>100.0%</b> (4/4)	100.0% (100/100)
	Promote heartfelt cardiovascular care through positive patient experience	21	Percentage of resolved documented complaints	<b>94.7</b> % (54/57)	90.0%	<b>95.0%</b> (19/20)	<b>93.3</b> % (28/30)	<b>95.5</b> % (42/44)	<b>96.2</b> % (51/53)	106.9% (96.2/90)
K		22	Decrease in patient safety related incidences	1.81% (242/ 133,695)	2.4%	<b>3.3</b> % (26/7,916)	<b>0.51</b> % (30/58,808)	<b>0.47</b> % (38/ 80,063)	<b>0.52</b> % ( <i>57/</i> 108,614)	461.5% (2.4/.52)
L	Upgrade hospital facilities for positive practice environment and stakeholders' satisfaction	23	Percentage of infrastructure projects completed as scheduled	<b>142.3</b> % (37/26)	95.0%	<b>81.3</b> % (13/16)	<b>182.4</b> % (31/17)	<b>182.4%</b> (31/17)	<b>175.0</b> % (28/16)	184.2% (175/95)
М	Provide technology solutions to improve operational efficiency	24	Number of new IT systems utilized by end-users	43	15	8	16	23	32	213.3% (32/15)

	SUPPORT PROCESSES									
	Objective	#	Measure	BL	Target	Actual (Q1)	Actual (Q2)	Actual (Q3)	Actual (Q4)	% ACC
	Ensure	25A	Percentage increase in gross revenue	10.9% (357.6M/ 3.29B	12.0%	-5.3% (21.4M/ 404.4M)	-48.7% (-1.1B/ 2.3B)	-51.3% (-1.4B/ 2.8B)	<b>-49.2</b> (-2.3B/ 4.8B)	-410.0%
	prudent and efficient asset management	25B	Percentage increase in Gross revenue	1.20B	10.0% from the previous quarter ( Re-set due to Covid)	1.20B (June Income)		<b>30.1</b> % (518.1 <i>M/</i> 1.20B)	<b>43.5</b> % (748.4M/ 1.72B)	435.0% (43.3/ 10)
		26A	Budget utilization rate	<b>83.4</b> % (2.13B/ 2.56B	100.0%	<b>16.5</b> % ( <u>286.3M</u> 1.7B)	<b>32.7</b> % ( <u>567.4M</u> 1.7B)	<b>49.4</b> % ( <u>858.5M</u> 1.7B)	<b>84.2</b> % (1.43B 1.70B)	<b>84.2</b> % ( <u>84.2</u> 100.0)
N		26B	Budget utilization rate	<b>83.4</b> % (2.13B/2.56B	<b>75%</b> ( Re-set due to Covid)	16.5% (286.3M 1.7B)	<b>32.7</b> % ( <u>567.4M</u> 1.7B)	<b>49.2</b> % (858.5M 1.7B)	<b>84.2</b> % (1.43B 1.70B	112.3% (84.2/ 75.0)
		27A	CapEx budget utilization rate	<b>69.7</b> % (143.0M/ 205.3M	100.0%	<b>8.5</b> % (4.2M/ 50.3M)	<b>30.6</b> % (15.4M/ 50.3M)	<b>37.3</b> % (18.7M/ 50.3M)	<b>88.9</b> % (44.7M 503M	<b>88.9</b> % (88.9 100.0)
		27B	CapEx budget utilization rate	<b>69.7</b> % (143.0M/ 205.3M	72.0% (Re-set due to Covid)	<b>8.5</b> % (4.2M/ 50.3M)	<b>30.6</b> % (15.4M/ 50.3M)	<b>37.3</b> % (18.7M/ 50.3M)	<b>88.9</b> % ( <u>44.7M</u> 50.3M	123.5% ( <u>88.9</u> 72.0)
		28	Zero out-of-stock essential drugs and supplies	<b>3.3</b> % (3/91)	10.0%	<b>2.53</b> % (2.3/92)	<b>3.6</b> % (3.3/92)	<b>3.4</b> % (3.1/92)	<b>4.2</b> % (3.9/92)	238.1% (10/4.2)

# #

#### PHILIPPINE HEART CENTER

## Balanced Scorecard 4th Quarter 2020 Summary Report



PERSPECTIVE	January - March 2020	January – June 2020	January – Sept 2020	January – Dec 2020
SOCIAL IMPACT (1-7 measures)	175.4%	135.9%	121.3%	111.1%
ORGANIZATION (8-9 measures)	88.7%	101.2%	101.2%	84.5%
INTERNAL PROCESS (10-11, 20-24 measures)	106.3%	180.7%	181.7%	180.5%
PEOPLE EMPOWERMENT (12-19 measures)	116.4%	99.5%	100.7%	114.3%
FUND RESOURCE (25-28 measures)	93.0%	-11.6%	-4.4%	227.2%
AVERAGE ACCOMPLISHMENT	116.0% Very Satisfactory	101.1% Satisfactory	100.1% Satisfactory	143.5% Outstanding

С	ARDIOVASCULAR PROCEDURES	BENCHMARK	PHC (Q1)	PHC (Q2)	PHC (Q3)	PHC (Q4)	Office Responsible
0017	Device Closure of Congenital Heart Disease-PDA	0% Morbidity (Cleveland Clinic 2015: 42 cases)	<b>0</b> % (0/47 cases)	<b>0</b> % (0/47 cases)	0% (0/53 cases))	0% (0/68 cases))	DPC- Invasive Cardiology; DAC- Invasive
2017	PCI Door to Balloon	90 minutes	31.2 minutes (CV Lab data only)	<b>45.2</b> minutes (CV Lab data )	<b>52 mins</b> (CV lab data )	<b>45.2 mins</b> (CV lab data )	DAC- Invasive Cardiology DAEC- ER
	Percutaneous Transmitral Commissurotomy	< 1% (Phil. Society of CV Catherization Inc)	<b>0</b> % (0/13)	<b>0</b> % (0/59)	0% (0/69)	0% (0/28)	DAC- Invasive Cardiology
2018	Close Follow-up of Discharged Patients through Telecare Nursing (Focus on post-reportable outcomes after 30 days)	Not Available	97.9% (469/47		98. (996/	Nursing- Telecare	
	Minimally Invasive Cardiac Surgery	0% (Cleveland Clinic, 256 Procedures)	<b>6.67</b> % (1/15 cases)	6.67% (1/15 cases)	<b>6.3</b> % (1/1 <b>6</b> cases)	5.88% (1/17cases)	DSA- Surgery
	Device Closure of Congenital Heart Disease-ASD (Adult + Pedia)	3%	<b>0</b> % (0/9)	<b>0</b> % (0/10)	0% (0/10)	0% (0/15)	DPC- Invasive Cardiology : DAC Invasive
2019	Device Closure of Congenital Heart Disease-VSD	3%	<b>0</b> % (0/4)	<b>0</b> % (0/4)	0% (0/5)	0% (0/8)	DPC- Invasive Cardiology
	Single Valvo Bongir	Mitral-5.8% ( Society of Thoracic Surgeons)	<b>0</b> % (0/44)	<b>0</b> % (0/46)	1.4% (1/70)	1.0% (1/100)	DSA- Surgery
	Single Valve Repair	Aortic-3.8% ( Society of Thoracic Surgeons)	<b>14.29</b> % (1 <i>/7</i> )	<b>14.29</b> % (1/7)	7.7% (1/13)	4.17% (1/24)	DSA- Surgery
	Transcatheter Aortic Valve Replacement	5.2% ( Society of Thoracic Surgeons, 2015)	<b>0</b> % (0/7)	<b>0</b> % (0/7)	<b>0</b> % (0/8)	<b>10</b> % (1/10)	DSA- Surgery
2020	Endovascular Aneurysm Repair	6.1% (American Heart Association)	<b>0</b> % (0/12)	<b>0</b> % (0/12)	<b>o</b> % (0/13)	<b>0</b> % (0/16)	DSA- Vascular Surgery
	Advanced Heart Failure Therapies						DAEC- Critical Care Division
	Best Practice in Blood Conservation						DAMS- Bloodbank
	Advanced Coronary Revascularization						DAC- Invasive Cardiology
2021	Radio Frequency Ablation Therapy	<2%	1.75% (9/514) 2009-2018	0% (0/17)	0% (0/17)	2.4% (1/42)	DAC- EPS
	Cardiovascular Clinical Trial Center						ETRS- Clinical Research
	Arterial Switch Operation	11% (World Database)	16.7%(1/6)	14.3%(1/7)	7.7% (1/13)	17.65% (3/17)	DPC- Clinical & Critical
2022	Neonatal Cardiac Surgery	20% (World Database)	16.2%(1/6)	16.2% (1/6)	16.2% (1/6)	35.3% (6/17)	DPC- Clinical & Critical
	Peripheral Endovascular Revascularization	< 1% (American Heart Association, 2017)					DSA- Vascular Surgery
Legend	d: Outcomes at par with global standards	Still with	low number of cases	Not yet at par	with global standards		

	NATIONAL POLICIES	Office Responsible						
0017	Policy on Health Facility Development of Regional Hospitals for Cardiac Specialty to Ensure Availability of Cardiovascular Care in 17 Regions (DOH)	Corp Plan (OSM)						
2017	Full Treatment of Rare Kawasaki Disease with IVIG for the Prevention of Coronary Aneurysm (Registry, Free IVIG DOH)	DPC						
2018	Philhealth Special Benefit (Free) Secondary Prophylaxis for all RFRHD Patients 5 to 25 years old	DPC						
2019	Philhealth Z-Benefit for Primary PCI in STEMI	DAC- Invasive Cardiology						
	Adoption of Employees' Wellness Program for all National Government Agencies	ETRS- Preventive Cardiology						
2020	Philhealth Z-Benefit Coverage for Mitral Valvuloplasty	DPC- Invasive Cardiology						
	Mandatory Neonatal Pulse-Oximetry in Newborns for Early Detection of Critical Congenital Heart  Disease as part of Philhealth-covered Newborn Screening	DPC						
0001	Mandatory Screening for all Grade 6 Students for Early Detection of Metabolic Syndrome for Cardiovascular Risk Reduction in Children	DPC						
2021	Philhealth Z-Benefit Coverage for PDA Device Closure	DPC						
2022	Philhealth OPD Package -Mandatory Cardiovascular Risk Screening for CAD for ages 40-45 years old							
Legend : Completed /Achieved On-going Not yet started								

Prepared by

GLORILYN JOY C. LACESTE, MA Psy

Planning Officer III

Office of Strategy Management

Reviewed by

: JULIET J. BALDERAS, MD, MSPH

Department Manager

Management Services Department

Noted by

: CRISELLE M. GALANG, RN, DNM

Deputy Executive Director

**Nursing Services** 

GILBERT C. VILBLA, MD

Deputy Executive Director

Education, Training and Research Services

JOSEPHINE M. GUILLERMO-LOPEZ, CPA, MBA

Deputy Executive Director

**Hospital Support Services** 

GERARDO S. MANZO, MD

Deputy Executive Director

**Medical Services** 

Approved by

DEL M. ABANILLA, MD

**Executive Director**